Orchard Therapeutics announces acceptance of biologics license application for OTL-200 in MLD and receives priority review

Orchard Therapeutics

18 September 2023 - PDUFA date set for 18 March 2024.

Orchard Therapeutics today announced the US FDA has accepted the filing of its biologics license application for OTL-200 in metachromatic leukodystrophy under priority review.

Read Orchard Therapeutics press release

Michael Wonder

Posted by:

Michael Wonder